A
Aurélien Marabelle
Researcher at Institut Gustave Roussy
Publications - 365
Citations - 21391
Aurélien Marabelle is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 60, co-authored 278 publications receiving 13479 citations. Previous affiliations of Aurélien Marabelle include Paris Descartes University & Stanford University.
Papers
More filters
Journal ArticleDOI
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Jean-Marie Michot,Camille Bigenwald,Stéphane Champiat,Michael Collins,Franck Carbonnel,Sophie Postel-Vinay,Amandine Berdelou,Andreea Varga,Ratislav Bahleda,Antoine Hollebecque,Christophe Massard,Alina Fuerea,Vincent Ribrag,A. Gazzah,J.P. Armand,N Amellal,Eric Angevin,Nicolas Noel,Celine Boutros,Christine Mateus,Caroline Robert,Jean-Charles Soria,Aurélien Marabelle,Olivier Lambotte +23 more
TL;DR: This review focuses on the mechanisms of IRAE generation, putative relationship between dysimmune toxicity and antitumour efficacy, as a basis for management guidelines.
Journal ArticleDOI
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurélien Marabelle,Dung T. Le,Paolo A. Ascierto,Anna Maria Di Giacomo,Ana De Jesus-Acosta,Jean Pierre Delord,Ravit Geva,Maya Gottfried,Nicolas Penel,Aaron R. Hansen,Sarina Anne Piha-Paul,Toshihiko Doi,Bo Gao,Hyun Cheol Chung,Jose A. Lopez-Martin,Yung-Jue Bang,Ronnie Shapira Frommer,Manisha H. Shah,Razi Ghori,Andrew K. Joe,Scott K. Pruitt,Luis A. Diaz +21 more
TL;DR: The study demonstrates the clinical benefit of anti-programmed death-1 therapy with pembrolizumab among patients with previously treated unresectable or metastatic MSI-H/dMMR noncolorectal cancer.
Journal ArticleDOI
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Aurélien Marabelle,Marwan Fakih,Juanita Lopez,Manisha H. Shah,Ronnie Shapira-Frommer,Kazuhiko Nakagawa,Hyun Cheol Chung,Hedy L. Kindler,Jose A. Lopez-Martin,Wilson H. Miller,Antoine Italiano,Steven Kao,Sarina Anne Piha-Paul,Jean Pierre Delord,Robert R. McWilliams,David Fabrizio,Deepti Aurora-Garg,Lei Xu,F. Jin,Kevin Norwood,Yung-Jue Bang +20 more
TL;DR: The association of high tissue TMB (tTMB-high) with outcomes in ten tumour-type-specific cohorts from the phase 2 KEYNOTE-158 study, which assessed the anti-PD-1 monoclonal antibody pembrolizumab in patients with selected, previously treated, advanced solid tumours, was prospectively explored.
Journal ArticleDOI
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
Stéphane Champiat,Stéphane Champiat,Laurent Dercle,Samy Ammari,Christophe Massard,Antoine Hollebecque,Sophie Postel-Vinay,Sophie Postel-Vinay,Nathalie Chaput,Alexander M.M. Eggermont,Aurélien Marabelle,Aurélien Marabelle,Jean-Charles Soria,Jean-Charles Soria,Charles Ferté,Charles Ferté +15 more
TL;DR: A novel aggressive pattern of hyperprogressive disease or HPD exists in a fraction of patients treated with anti-PD-1/PD-L1 monotherapy, and this observation raises some concerns about treating elderly patients (>65 years old), and suggests further study of this phenomenon.
Journal ArticleDOI
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Celine Boutros,Ahmad A. Tarhini,Emilie Routier,Olivier Lambotte,Francois Leroy Ladurie,Franck Carbonnel,Hassane Izzeddine,Aurélien Marabelle,Stéphane Champiat,Armandine Berdelou,Emilie Lanoy,M. Texier,C. Libenciuc,Alexander M.M. Eggermont,Alexander M.M. Eggermont,Jean-Charles Soria,Jean-Charles Soria,Jean-Charles Soria,Christine Mateus,Caroline Robert,Caroline Robert,Caroline Robert +21 more
TL;DR: The authors describe the adverse event profile of checkpoint inhibitors targeting CTLA-4 and PD-1, used both as monotherapies and in combination and aim to provide some general guidelines, based upon the mechanisms of action of these therapies and on the management of these immune-related adverse events.